Back to Journals » OncoTargets and Therapy » Volume 14

IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients

Authors Yuan Z, Zhao Z, Hu H, Zhu Y, Zhang W, Tang Q, Huang R, Gao F, Zou C, Wang G, Wang X

Received 3 October 2020

Accepted for publication 18 January 2021

Published 11 February 2021 Volume 2021:14 Pages 967—977

DOI https://doi.org/10.2147/OTT.S285171

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Jianmin Xu


Ziming Yuan,1 Zhixun Zhao,2 Hanqing Hu,1 Yihao Zhu,1 Weiyuan Zhang,1 Qingchao Tang,1 Rui Huang,1 Feng Gao,1 Chaoxia Zou,3 Guiyu Wang,1 Xishan Wang1,2

1Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China; 2Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 3Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China

Correspondence: Xishan Wang Email wxshan_1208@126.com
Guiyu Wang Email guiywang@163.com

Background: The liver is the most frequent site for metastatic spread in colorectal cancer (CRC) patients, and these patients have much poorer prognosis than those without metastasis. Previous studies have shown that IgG Fc binding protein (FCGBP) plays important roles in tumorigenesis, progression, and prognosis, but its role in CRC metastasis remains unclear.
Purpose: In this study, we are aimed to explore the significance of FCGBP in liver metastatic CRC (LMCRC) patients.
Methods: We analyzed the expression of FCGBP RNA between CRC primary samples and liver metastatic samples in the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA). Next, we assessed the expression of FCGBP protein in 135 paired primary CRC (PC) samples and LMCRC samples. Finally, we explored the relationship between the expression features and clinicopathological characteristics.
Results: The expression data of FCGBP were obtained from the GEO and TCGA databases. FCGBP RNA expression was evaluated between primary lesions (PC) and liver metastatic lesions (LM). FCGBP RNA was down-regulated in PC and LM, and especially lower in LM (p< 0.001). Next, the expression of FCGBP protein was evaluated by an immunohistochemistry array in 135 paired primary tumor tissues and metastatic tissues. We found that FCGBP protein was down-regulated in primary lesions and metastatic lesions, especially in metastatic lesions. According to the immunohistochemistry score (SI), each cohort was divided into FCGBP-positive (SI=4– 12) and FCGBP-negative (SI=0– 3) groups. In both groups, the levels of CEA (PC group, 3.880 vs 77.049, p< 0.001; LM group, 3.890 vs 14.239, p=0.008) and CA19-9 (PC group, 8.610 vs 111.700, p< 0.001; LM group, 7.660 vs 19.380, p=0.037) were lower than those in the FCGBP-negative group. FCGBP positivity in the LM cohort was an independent risk factor in both overall survival (HR 1.573, 95% Cl [1.017– 2.433], p=0.042) and disease-free survival (HR 1.869, 95% Cl [1.256– 2.781], p=0.002).
Conclusion: This study found a relationship between FCGBP expression and clinical information of LMCRC patients, and found that FCGBP expression decreased with disease development. The expression of FCGBP in liver metastasis is associated with both the overall and progression-free survival. Our results show that FCGBP could be a promising prognostic factor for LMCRC.

Keywords: colorectal cancer, IgG Fc binding protein, liver metastasis, prognosis, biomarker

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]